Format

Send to

Choose Destination
Methods Mol Biol. 2020;2060:429-454. doi: 10.1007/978-1-4939-9814-2_27.

The Murine Intravaginal HSV-2 Challenge Model for Investigation of DNA Vaccines.

Author information

1
Department of Medicine, University of Washington, Seattle, WA, USA.
2
Department of Medicine, University of Washington, Seattle, WA, USA. viralimm@u.washington.edu.
3
Department of Laboratory Medicine, University of Washington, Seattle, WA, USA. viralimm@u.washington.edu.
4
Department of Global Health, University of Washington, Seattle, WA, USA. viralimm@u.washington.edu.
5
Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. viralimm@u.washington.edu.
6
Benaroya Research Institute, Seattle, WA, USA. viralimm@u.washington.edu.

Abstract

DNA vaccines have been licensed in veterinary medicine and have promise for humans. This format is relatively immunogenic in mice and guinea pigs, the two principle HSV-2 animal models, permitting rapid assessment of vectors, antigens, adjuvants, and delivery systems. Limitations include the relatively poor immunogenicity of naked DNA in humans and the profound differences in HSV-2 pathogenesis between host species. Herein, we detail lessons learned investigating candidate DNA vaccines in the progesterone-primed female mouse vaginal model of HSV-2 infection as a guide to investigators in the field.

KEYWORDS:

Animal model; Antibody; DNA vaccine; Dorsal root ganglia; Herpes simplex virus; Latency; Polymerase chain reaction

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center